Puma Biotechnology announced strong financial results for the fourth quarter of 2024, with net income increasing to $19.3 million and product revenue reaching $54.4 million. The company also reported positive net income for the third consecutive year, driven by commercial performance and strategic initiatives.
Product revenue, net, for Q4 2024 was $54.4 million, an increase from $53.2 million in Q4 2023.
Net income for Q4 2024 was $19.3 million, or $0.39 per basic and diluted share, up from $12.3 million in Q4 2023.
Non-GAAP adjusted net income for Q4 2024 was $21.1 million, or $0.43 per basic and diluted share.
Net cash provided by operating activities for Q4 2024 was $15.6 million, compared to $10.5 million in Q4 2023.
Puma Biotechnology provided financial outlook for the first quarter and full year 2025, anticipating continued revenue generation and positive net income.
Analyze how earnings announcements historically affect stock price performance